|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global Cancer Statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Clarke R, Currier S, Kaplan O, Lovelace E,
Boulay V, Gottesman MM and Dickson RB: Effect of P-glycoprotein
expression on sensitivity to hormones in MCF-7 human breast cancer
cells. J Natl Cancer Inst. 84:1506–1512. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Robert J: Resistance to cytotoxic agents.
Curr Opin Pharmacol. 1:353–357. 2001. View Article : Google Scholar
|
|
4
|
Avendaño C and Menéndez JC: Inhibitors of
multidrug resistance to antitumor agents (MDR). Curr Med Chem.
9:159–193. 2002.PubMed/NCBI
|
|
5
|
Ross DD: Novel mechanisms of drug
resistance in leukemia. Leukemia. 14:467–473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan B, Piwnica-Worms D and Ratner L:
Multidrug resistance transporters and modulation. Curr Opin Oncol.
12:450–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mayer LD and Shabbits JA: The role for
liposomal drug delivery in molecular and pharmacological strategies
to overcome multidrug resistance. Cancer Metastasis Rev. 20:87–93.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu HJ, Wang JS, Guo QL, Jiang Y and Liu
GQ: Reversal of P-glycoprotein mediated multidrug resistance in
K562 cell line by a novel synthetic calmodulin inhibitor, E6. Biol
Pharm Bull. 28:1974–1978. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou J, Liu M, Aneja R, Chandra R, Lage H
and Joshi HC: Reversal of P-glycoprotein-mediated multidrug
resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer
Res. 66:445–452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CW, et al: Cancer chemopreventive activity of
resveratrol, a natural product derived from grapes. Science.
275:218–220. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kundu JK and Surh YJ: Cancer
chemopreventive and therapeutic potential of resveratrol:
mechanistic perspectives. Cancer Lett. 269:243–261. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goswami SK and Das DK: Resveratrol and
chemoprevention. Cancer Lett. 284:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bishayee A: Cancer prevention and
treatment with resveratrol: from rodent studies to clinical trials.
Cancer Prev Res (Phila). 2:409–418. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang F, Huang ZJ, Chen J and Wang JL:
Studies of several polyphenolses on multidrug resistance to human
breast carcinoma MCF-7/ADM Cell. J Pract Oncol. 24:121–123.
2009.(In Chinese).
|
|
17
|
Al-Abd AM, Mahmoud AM, El-Sherbiny GA,
El-Moselhy MA, Nofal SM, El-Latif HA, et al: Resveratrol enhances
the cytotoxic profile of docetaxel and doxorubicin in solid tumour
cell lines in vitro. Cell Prolif. 44:591–601. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hansen MB, Nielsen SE and Berg K:
Re-examination and further development of a precise and rapid dye
method for measuring cell growth/cell kill. J Immunol Methods.
119:203–210. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chambers SK, Hait WN, Kacinski BM, Keyes
SR and Handschumacher RE: Enhancement of anthracycline growth
inhibition in parent and multidrug resistant Chinese hamster ovary
cells by cyclosporin A and its analogues. Cancer Res. 49:6275–6279.
1989.PubMed/NCBI
|
|
20
|
Ganapathi R, Grabowski D, Rouse W and
Riegler F: Differential effect of the calmodulin inhibitor
trifluoperazine on cellular accumulation, retention, and
cytotoxicity of anthracyclines in doxorubicin
(adriamycin)-resistant P388 mouse leukemia cells. Cancer Res.
44:5056–5061. 1984.
|
|
21
|
Marques FZ, Markus MA and Morris BJ:
Resveratrol: cellular actions of a potent natural chemical that
confers a diversity of health benefits. Int J Biochem Cell Biol.
41:2125–2128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pozo-Guisado E, Merino JM, Mulero-Navarro
S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A and
Fernandez-Salguero PM: Resveratrol-induced apoptosis in MCF-7 human
breast cancer cells involves a caspase-independent mechanism with
downregulation of Bcl-2 and NF-kappaB. Int J Cancer. 115:74–84.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Benitez DA, Pozo-Guisado E,
Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA:
Mechanisms involved in resveratrol-induced apoptosis and cell cycle
arrest in prostate cancer-derived cell lines. J Androl. 28:282–293.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loo TW and Clarke DM: Location of the
rhodamine-binding site in the human multidrug resistance
P-glycoprotein. J Biol Chem. 277:44332–44338. 2002. View Article : Google Scholar : PubMed/NCBI
|
